AbbVie/ABBV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
ABBV
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology
Headquarters
North Chicago, United States
Employees
50,000
Website
www.abbvie.com
AbbVie Metrics
BasicAdvanced
$301B
Market cap
50.69
P/E ratio
$3.36
EPS
0.59
Beta
$6.06
Dividend rate
3.56%
Dividend yield
Price and volume
Market cap
$301B
Beta
0.59
Dividend rate
$6.06
Financial strength
Current ratio
0.936
Quick ratio
0.723
Long term debt to equity
797.341
Total debt to equity
924.059
Dividend payout ratio (TTM)
177.71%
Interest coverage (TTM)
7.50%
Management effectiveness
Return on assets (TTM)
7.71%
Return on equity (TTM)
56.24%
Valuation
Price to earnings (TTM)
50.69
Price to revenue (TTM)
5.54
Price to book
29.04
Price to tangible book (TTM)
-3.43
Price to free cash flow (TTM)
13.76
Dividend yield (TTM)
3.56%
Growth
Revenue change (TTM)
-4.12%
Earnings per share change (TTM)
-20.77%
3-year revenue growth
2.72%
3-year earnings per share growth
4.87%
3-year dividend per share growth
6.90%
What the Analysts think about AbbVie
Analyst Ratings
Majority rating from 30 analysts.
AbbVie Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12B
-13.92%
Net income
$1.4B
66.55%
Profit margin
11.12%
93.73%
AbbVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.91
$2.95
$2.79
$2.31
-
Expected
$2.81
$2.86
$2.77
$2.23
$3.05
Surprise
3.69%
3.25%
0.84%
3.76%
-
AbbVie News
AllArticlesVideos
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
PRNewsWire·2 months ago
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
Business Wire·2 months ago
AbbVie Tracking for New Highs in 2024
MarketBeat·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
Jul
15
AbbVie
Dividend·Ex-dividend
Aug
15
AbbVie
Dividend·Payment
$1.55
Per share
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $301B as of July 03, 2024.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 50.69 as of July 03, 2024.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $6.06 and the yield is 3.56%. AbbVie has a payout ratio of 177.71% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for August 15, 2024.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell AbbVie stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.